Phase 2
Completed N=11
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
Source: ClinicalTrials.gov NCT04452669 ↗Enrolled (actual)
11
Serious AEs
45.5%
Results posted
Jul 2025
Primary outcomePrimary: Change in Respiratory Failure — 3; 2 Participants
Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Respiratory Failure |
3; 2 | — |
| PRIMARY Change in Cardiac/Circulatory Failure |
0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Confirmed COVID-19 positive by RT-PCR test
- Patients who require invasive mechanical ventilation.
- Consent or professional consent obtained
Exclusion Criteria
- Patients on ECMO support.
- Patients receiving another inhalation research medication or inhaled nitric oxide.
- Not expected to survive for 48 hours.
- Allergy to Epoprostenol and its diluent
Data sourced from ClinicalTrials.gov (NCT04452669). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.